Vyndaqel a bright spot as Pfizer comes under pressure

The top line was however dragged down by the onset of generic competition in the US to severe pain drug Lyrica (pregabalin), which plunged to $433m from $1.32bn a year ... Upjohn sales were weak in the quarter, down 16% largely because of the impact of

Pfizer raises forecast following growth of biopharma business

This was primarily due to volume declines of anti-seizure drug Lyrica (pregabalin), due to multi-source generic competition that began in July 2019 in the US.

Daiichi Sankyo starts mirogabalin trial in spinal injury pain

rival to Pfizer’s big-selling Lyrica (pregabalin) brand which brought in $4.7bn last year despite generic competition in some markets. ... Like the original Lyrica formulation Daiichi Sankyo’s drug is dosed twice-daily.

The handover: Pfizer reshapes itself for a new era

These new products will help offset the patent expiry of one of Pfizer’s biggest products, pain treatment Lyrica, which will see generics arrive at the end of December. ... autonomous. Created in the summer reshuffle, the Established Medicines division

1 2 3 4 5 6 7 8 9 [ Next 5 results ]